{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:38:56Z","timestamp":1794674336321,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["Foundation for the National Institutes of Health"],"award-info":[{"award-number":["Foundation for the National Institutes of Health"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinical CAR T-cell therapy using integrating vector systems represents a promising approach for the treatment of hematological malignancies. Lentiviral and \u03b3-retroviral vectors are the most commonly used vectors in the manufacturing process. However, the integration pattern of these viral vectors and subsequent effect on CAR T-cell products is still unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a modified viral integration sites analysis (VISA) pipeline to evaluate viral integration events around the whole genome in pre-infusion CAR T-cell products. We compared the differences of integration pattern between lentiviral and \u03b3-retroviral products. We also explored whether the integration sites correlated with clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that \u03b3-retroviral vectors were more likely to insert than lentiviral vectors into promoter, untranslated, and exon regions, while lentiviral vector integration sites were more likely to occur in intron and intergenic regions. Some integration events affected gene expression at the transcriptional and post-transcriptional level. Moreover, \u03b3-retroviral vectors showed a stronger impact on the host transcriptome. Analysis of individuals with different clinical outcomes revealed genes with differential enrichment of integration events. These genes may affect biological functions by interrupting amino acid sequences and generating abnormal proteins, instead of by affecting mRNA expression. These results suggest that vector integration is associated with CAR T-cell efficacy and clinical responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We found differences in integration patterns, insertion hotspots and effects on gene expression vary between lentiviral and \u03b3-retroviral vectors used in CAR T-cell products and established a foundation upon which we can conduct further analyses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-022-03729-5","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T22:03:01Z","timestamp":1667944981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products"],"prefix":"10.1186","volume":"20","author":[{"given":"Lipei","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongye","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingdong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Fuksenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Pelayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Norberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hinrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Highfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya R.","family":"Panch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"3729_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"3729_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"3729_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, et al. CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase i anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020;38:1938\u201350.","journal-title":"J Clin Oncol"},{"key":"3729_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3109\/10409238.2015.1102859","volume":"51","author":"E Serrao","year":"2016","unstructured":"Serrao E, Engelman AN. Sites of retroviral DNA integration: from basic research to clinical applications. Crit Rev Biochem Mol Biol. 2016;51:26\u201342.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"3729_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","volume":"58","author":"D Escors","year":"2010","unstructured":"Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz). 2010;58:107\u201319.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"3729_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307\u201312.","journal-title":"Nature"},{"key":"3729_CR7","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, Ahlman MA, Stetler-Stevenson M, Yuan C, Guo S, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3:2317\u201322.","journal-title":"Blood Adv"},{"key":"3729_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","volume":"26","author":"K Cornetta","year":"2018","unstructured":"Cornetta K, Duffy L, Turtle CJ, Jensen M, Forman S, Binder-Scholl G, Fry T, Chew A, Maloney DG, June CH. Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. Mol Ther. 2018;26:280\u20138.","journal-title":"Mol Ther"},{"key":"3729_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2018.08.006","volume":"10","author":"K Cornetta","year":"2018","unstructured":"Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O\u2019Cearbhaill R, et al. Screening clinical cell products for replication competent retrovirus: the national gene vector biorepository experience. Mol Ther Methods Clin Dev. 2018;10:371\u20138.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3729_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval J-L, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255\u20136.","journal-title":"N Engl J Med"},{"key":"3729_CR11","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Investig. 2008;118:3132\u201342.","journal-title":"J Clin Investig"},{"key":"3729_CR12","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1128\/JVI.00011-14","volume":"88","author":"SS De Ravin","year":"2014","unstructured":"De Ravin SS, Su L, Theobald N, Choi U, Macpherson JL, Poidinger M, Symonds G, Pond SM, Ferris AL, Hughes SH, et al. Enhancers are major targets for murine leukemia virus vector integration. J Virol. 2014;88:4504\u201313.","journal-title":"J Virol"},{"key":"3729_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.omtm.2016.11.002","volume":"4","author":"E Sherman","year":"2016","unstructured":"Sherman E, Nobles C, Berry CC, Six E, Wu Y, Dryga A, Malani N, Male F, Reddy S, Bailey A, et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol therapy Methods Clin Dev. 2016;4:39\u201349.","journal-title":"Mol therapy Methods Clin Dev"},{"key":"3729_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41596-018-0087-5","volume":"14","author":"RT Timms","year":"2019","unstructured":"Timms RT, Tchasovnikarova IA, Lehner PJ. Differential viral accessibility (DIVA) identifies alterations in chromatin architecture through large-scale mapping of lentiviral integration sites. Nat Protoc. 2019;14:153\u201370.","journal-title":"Nat Protoc"},{"key":"3729_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12864-020-6647-4","volume":"21","author":"DW Wells","year":"2020","unstructured":"Wells DW, Guo S, Shao W, Bale MJ, Coffin JM, Hughes SH, Wu X. An analytical pipeline for identifying and mapping the integration sites of HIV and other retroviruses. BMC Genomics. 2020;21:216\u20136.","journal-title":"BMC Genomics"},{"key":"3729_CR16","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.3390\/cancers13236104","volume":"13","author":"K-B Huang","year":"2021","unstructured":"Huang K-B, Guo S-J, Li Y-H, Zhang X-K, Chen D, Spiess PE, Li Z-S, Deng C-Z, Chen J-P, Zhou Q-H, et al. Genome-wide profiling reveals HPV integration pattern and activated carcinogenic pathways in penile squamous cell carcinoma. Cancers. 2021;13:6104.","journal-title":"Cancers"},{"key":"3729_CR17","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1073\/pnas.1919259117","volume":"117","author":"W Wang","year":"2020","unstructured":"Wang W, Fasolino M, Cattau B, Goldman N, Kong W, Frederick MA, McCright SJ, Kiani K, Fraietta JA, Vahedi G. Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels. Proc Natl Acad Sci U S A. 2020;117:5442\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3729_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R, Gersuk V, Riddell SR, Maloney DG, Wohlfahrt ME, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun. 2020;11:219.","journal-title":"Nat Commun"},{"key":"3729_CR19","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1038\/sj.onc.1207006","volume":"22","author":"MJ Ferber","year":"2003","unstructured":"Ferber MJ, Thorland EC, Brink AATP, Rapp AK, Phillips LA, McGovern R, Gostout BS, Cheung TH, Chung TKH, Fu WY, Smith DI. Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma. Oncogene. 2003;22:7233\u201342.","journal-title":"Oncogene"},{"key":"3729_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/path.2713","volume":"221","author":"M Peter","year":"2010","unstructured":"Peter M, Stransky N, Couturier J, Hup\u00e9 P, Barillot E, de Cremoux P, Cottu P, Radvanyi F, Sastre-Garau X. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol. 2010;221:320\u201330.","journal-title":"J Pathol"},{"key":"3729_CR21","doi-asserted-by":"publisher","first-page":"785169","DOI":"10.3389\/fcimb.2021.785169","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Han Z, Ruan Y, Liu M, Cao G, Li C, Li F. HPV16-LINC00393 Integration Alters Local 3D genome architecture in cervical cancer cells. Front Cell Infect Microbiol. 2021;11:785169\u20139.","journal-title":"Front Cell Infect Microbiol"},{"key":"3729_CR22","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-07-2776","volume":"68","author":"I Kraus","year":"2008","unstructured":"Kraus I, Driesch C, Vinokurova S, Hovig E, Schneider A, von Knebel Doeberitz M, D\u00fcrst M. The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res. 2008;68:2514.","journal-title":"Cancer Res"},{"key":"3729_CR23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/sj.onc.1206170","volume":"22","author":"EC Thorland","year":"2003","unstructured":"Thorland EC, Myers SL, Gostout BS, Smith DI. Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene. 2003;22:1225\u201337.","journal-title":"Oncogene"},{"key":"3729_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/hum.2020.215","volume":"32","author":"S Choi","year":"2021","unstructured":"Choi S, Pegues MA, Lam N, Geldres C, Vanasse D, Kochenderfer JN. Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains. Hum Gene Ther. 2021;32:730\u201343.","journal-title":"Hum Gene Ther"},{"key":"3729_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun. 2020;11:283.","journal-title":"Nat Commun"},{"key":"3729_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","volume":"29","author":"C Amatya","year":"2021","unstructured":"Amatya C, Pegues MA, Lam N, Vanasse D, Geldres C, Choi S, Hewitt SM, Feldman SA, Kochenderfer JN. Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7. Mol Ther. 2021;29:702\u201317.","journal-title":"Mol Ther"},{"key":"3729_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021;27:419\u201325.","journal-title":"Nat Med"},{"key":"3729_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12967-020-02358-0","volume":"18","author":"A Lu","year":"2020","unstructured":"Lu A, Liu H, Shi R, Cai Y, Ma J, Shao L, Rong V, Gkitsas N, Lei H, Highfill SL, et al. Application of droplet digital PCR for the detection of vector copy number in clinical CAR\/TCR T cell products. J Transl Med. 2020;18:191.","journal-title":"J Transl Med"},{"key":"3729_CR29","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R Package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"3729_CR30","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/s41598-022-06830-3","volume":"12","author":"L Shao","year":"2022","unstructured":"Shao L, Iyer A, Zhao Y, Somerville R, Panch S, Pelayo A, Stroncek DF, Jin P. Identification of genomic signatures in bone marrow associated with clinical response of CD19 CAR T-cell therapy. Sci Rep. 2022;12:2830.","journal-title":"Sci Rep"},{"key":"3729_CR31","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1093\/nar\/gkaa1152","volume":"49","author":"J van Haasteren","year":"2021","unstructured":"van Haasteren J, Munis AM, Gill DR, Hyde SC. Genome-wide integration site detection using Cas9 enriched amplification-free long-range sequencing. Nucleic Acids Res. 2021;49:e16.","journal-title":"Nucleic Acids Res"},{"key":"3729_CR32","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1101\/gr.6286907","volume":"17","author":"GP Wang","year":"2007","unstructured":"Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 2007;17:1186\u201394.","journal-title":"Genome Res"},{"key":"3729_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrm3525","volume":"14","author":"AR Kornblihtt","year":"2013","unstructured":"Kornblihtt AR, Schor IE, All\u00f3 M, Dujardin G, Petrillo E, Mu\u00f1oz MJ. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 2013;14:153\u201365.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3729_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3892\/br.2014.407","volume":"3","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu J, Huang BO, Xu Y-M, Li J, Huang L-F, Lin J, Zhang J, Min Q-H, Yang W-M, Wang X-Z. Mechanism of alternative splicing and its regulation. Biomedical Rep. 2015;3:152\u20138.","journal-title":"Biomedical Rep"},{"key":"3729_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2020","unstructured":"Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Investig. 2020;130:673\u201385.","journal-title":"J Clin Investig"},{"key":"3729_CR36","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395.","journal-title":"Blood"},{"key":"3729_CR37","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang H-W, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138:2469\u201384.","journal-title":"Blood"},{"key":"3729_CR38","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR\u2013T cells of defined CD4+:CD8 + composition in adult B cell ALL patients. J Clin Investig. 2016;126:2123\u201338.","journal-title":"J Clin Investig"},{"key":"3729_CR39","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang W-C, et al. Phase 1 studies of central memory\u2013derived CD19 CAR T\u2013cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127:2980\u201390.","journal-title":"Blood"},{"key":"3729_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O\u2019Connor RS, Hwang W-T, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"3729_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20\u20138.","journal-title":"Nat Med"},{"key":"3729_CR42","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","volume":"24","author":"KT Mueller","year":"2018","unstructured":"Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24:6175.","journal-title":"Clin Cancer Res"},{"key":"3729_CR43","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI125423","volume":"129","author":"OC Finney","year":"2019","unstructured":"Finney OC, Brakke H, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell B, Orentas RJ, Li D, Gardner R, Jensen MC. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Investig. 2019;129:2123\u201332.","journal-title":"J Clin Investig"},{"key":"3729_CR44","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/2326-6066.CIR-20-0922","volume":"9","author":"TR Emmons","year":"2021","unstructured":"Emmons TR, Giridharan T, Singel KL, Khan ANMNH, Ricciuti J, Howard K, Silva-Del Toro SL, Debreceni IL, Aarts CEM, Brouwer MC, et al. Mechanisms driving neutrophil-induced T-cell immunoparalysis in ovarian cancer. Cancer Immunol Res. 2021;9:790.","journal-title":"Cancer Immunol Res"},{"key":"3729_CR45","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1172\/jci.insight.122311","volume":"4","author":"KL Singel","year":"2019","unstructured":"Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI insight. 2019;4:28.","journal-title":"JCI insight"},{"key":"3729_CR46","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.1371\/journal.pbio.0020234","volume":"2","author":"RS Mitchell","year":"2004","unstructured":"Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2:E234-4.","journal-title":"PLoS Biol"},{"key":"3729_CR47","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1093\/nar\/gkt1399","volume":"42","author":"MC LaFave","year":"2014","unstructured":"LaFave MC, Varshney GK, Gildea DE, Wolfsberg TG, Baxevanis AD, Burgess SM. MLV integration site selection is driven by strong enhancers and active promoters. Nucleic Acids Res. 2014;42:4257\u201369.","journal-title":"Nucleic Acids Res"},{"key":"3729_CR48","first-page":"147","volume":"67","author":"S Desfarges","year":"2012","unstructured":"Desfarges S, Ciuffi A. Viral integration and consequences on host gene expression. Viruses. 2012;67:147\u201375.","journal-title":"Viruses"},{"key":"3729_CR49","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/v14010086","volume":"14","author":"S Janjetovic","year":"2022","unstructured":"Janjetovic S, Hinke J, Balachandran S, Aky\u00fcz N, Behrmann P, Bokemeyer C, Dierlamm J, Murga Penas EM. Non-Random Pattern of Integration for Epstein-Barr Virus with Preference for Gene-Poor Genomic Chromosomal Regions into the Genome of Burkitt Lymphoma Cell Lines. Viruses. 2022;14:86.","journal-title":"Viruses"},{"key":"3729_CR50","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, De Ridder D, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118:3143\u201350.","journal-title":"J Clin Invest"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03729-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03729-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T08:04:23Z","timestamp":1668153863000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03729-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03729-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript has been approved by all authors for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"514"}}